PrEP: Preventative HIV drug highly effective
The study confirmed that an “in use” preventive drug that does not allow the infection of HIV into the body.
Studies have described their findings for 24,000 people who took the survey in England as “reassuring”.
Health clinics are already giving out thousands of PrEPs to patients.
The charity HIV Terrence Higgins Trust also call for simpler access to this medication as some people, even women among them are unaware about its existence.
UK HSA, the lead agency for the Prep Impact trial with Westminster Hospital NHSF Trust, indicated that this was the single biggest observational trial in the world.
NHS England funded it and it took place in 157 sexual health clinics in England from October 2017 to July 2020.
Study revealed among the use of PrEP, or, pre-exposure prophylaxis … By using it on a daily basis, one could reduce the chances of getting infected with HIV by more than 86%. Such assessment takes account of irregular and/or incorrect implementation. The proposed medication was found to be 99% efficacious in clinical trials.
Dr John Saunders, a consultant in sexual health and HIV who worked on the study, said: This case study has indeed reaffirmed the efficacy of preventive therapy in blocking HIV infection and it is indeed the first time when such impact as was found among smaller-scale studies, at scale and based on primary care clinics.
However, it noted that “much more needs to be done” to ensure that more people especially minorities knew about and could easily access PreP.
Debbie Laycock, head of policy, said: Currently, we believe that some selected sections of people do not receive these services when they need them.
“The majority of women are not aware that PrEP exists,” she finished off.
She stated that the charity is advocating for PrEP to be made available in pharmacies and online in order to increase access to it.
Dr. Saunders stated that while the drug’s therapeutic success had been demonstrated, this study offered additional vital information regarding how it was utilized.
“Before, we didn’t know how many people would want it, take it, or how long they would stay on it for,” he told me.
“Now we know who is being prescribed it and we can work with clinics to try and get more people to take it.”
He stated that “real-world effectiveness” was determined by a variety of factors, including whether the medicine was taken correctly.
According to Harry Dodd, who has participated in several Prep trials, taking this drug empowered him since he stopped being afraid of HIV infection.
It is refreshing to me as it will take many years that I can no longer remember and liberation of not think about that subject for almost one decade that is amazing indeed. In addition, I believe in loving without any fear which I did not have with former partners who have HIV for such kind
Mr Dodd of 33 years old from London’s northern part indicated that many people were likely to have concern taking the drug, as it is sexually linked. Yet, with such a viewpoint, he pointed out, the usage of PreP can make the situation with HIV stig
By taking this drug, it will be possible to attain the UKSBA goal of zero new HIV transmissions in 2030.
Dr Saunders also noted that although gay and bisexual men were those who were most likely to consume this drug, almost any individual from other groups like ‘straight women’ could profit from having this substance.
Pre-exposure prophylaxis (PrEP) is a combination of existing anti retro viral agents that disrupt the replication process and attachment of the virus onto cells thereby preventing its entry into the system.
One can either take it as a daily pill or on “event” basis, like before having sex.
These earlier findings as part of this research and earlier clinical trials underpin the recent decision to provide national coverage for this treatment within the NHS in England in 2020.
Due to a big population sample and peer reviewed process, the publication of this study’s findings on Lancet HIV has recently occurred.
“Not only did the trial directly prevent many cases of HIV, help normalise the use of PrEP, remove stigma, and pave the way for a routinely commissioned clinically and cost effective PrEP service; but it also made a very real contribution towards our goal of ending new cases of HIV by 2030,” said John Stewart, National Director for Specialised Commissioning at NHS England and co-Chair of the PrEP Impact Trial Oversight Board.
“We are delighted that PrEP has proven to be highly effective in reducing the risk of getting HIV and people can access it for free from sexual health service.”